Incorrect password
evipedia.ai Suggest Edit

Low-Dose Aspirin for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: Baby Aspirin, Acetylsalicylic Acid, ASA, Low-Dose ASA

Motivation

Low-dose aspirin (acetylsalicylic acid) is among the oldest and most widely used oral medications. At doses of 75–100 mg per day, it irreversibly disables platelet clotting machinery for the lifespan of each affected platelet, an effect that became the basis for decades of cardiovascular prevention. More recently, accumulating data have suggested it may also influence cancer biology, particularly colorectal tumors.

For most of the late twentieth century, daily low-dose aspirin was widely taken by adults without established heart disease in the hope of preventing first heart attacks and strokes. A wave of large trials substantially changed that picture by quantifying how much of the cardiovascular benefit was offset by bleeding, and a signal of increased cancer-related mortality in older adults added a further layer of complexity.

This review examines the evidence on low-dose aspirin’s effects on cardiovascular events, cancer outcomes, bleeding risk, and the practical considerations that shape its use within a longevity-oriented strategy.

Benefits - Risks - Protocol - Conclusion

A curated selection of expert resources covering low-dose aspirin’s cardiovascular and oncologic biology, the post-2018 evidence shift, and practical considerations for longevity-oriented use.

  • AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense? - Peter Attia

    Includes an in-depth segment on the evolving evidence for aspirin in primary cardiovascular prevention, Attia’s analysis of the ASPREE, ASCEND, and ARRIVE trials, and the factors he weighs in his own risk-benefit calculus for a longevity-oriented audience.

  • Q&A #30 with Dr. Rhonda Patrick (12/4/2021) - Rhonda Patrick

    Includes a detailed discussion of the unexpected ASPREE finding that aspirin increased cancer-related mortality in healthy older adults, hypothesized mechanisms involving aspirin’s effects on immune surveillance, and how these findings might influence aspirin decisions across age groups.

  • 4 Natural Alternatives to Aspirin - Chris Kresser

    A critical assessment of aspirin’s risk-benefit profile for primary prevention, arguing that bleeding risks outweigh cardiovascular benefits in most healthy individuals, and presenting evidence-based alternatives such as fish oil, curcumin, and nattokinase as potentially safer antiplatelet and anti-inflammatory options.

  • Why Many People May Not Need Aspirin Today - William Faloon

    A historical perspective from an organization that recommended daily aspirin since 1983, now reassessing its position in light of the 2018 trial results, explaining why modern improvements in cardiovascular risk factors (statin use, smoking cessation, blood pressure control) may have reduced aspirin’s absolute benefit in primary prevention.

  • Fifty years with aspirin and platelets - Patrono, 2023

    A narrative review by Carlo Patrono, one of the principal investigators of aspirin’s antiplatelet pharmacology, summarizing the half-century arc of the science: dose-response biology, the irreversible cyclooxygenase-1 mechanism, primary versus secondary prevention evidence, and current open questions in cardiology and oncology.

Substantive standalone aspirin content from Andrew Huberman could not be located on hubermanlab.com; aspirin appears only briefly within broader pain and longevity episodes.

Grokipedia

Aspirin

A reference article covering aspirin’s chemistry as acetylsalicylic acid, the willow-bark and salicin history, the cyclooxygenase mechanism, the primary versus secondary prevention distinction, the 2018 trial cluster (ASPREE, ASCEND, ARRIVE) that reshaped guidelines, and the emerging colorectal-cancer chemoprevention discussion.

Examine

No dedicated Examine.com article exists for aspirin (Examine.com does not typically cover prescription or pharmaceutical agents).

ConsumerLab

No dedicated ConsumerLab article exists for aspirin (ConsumerLab does not typically cover prescription or pharmaceutical medications).

Systematic Reviews

A selection of recent systematic reviews and meta-analyses examining low-dose aspirin across cardiovascular, oncologic, and bleeding endpoints in humans.

Mechanism of Action

Low-dose aspirin exerts its primary therapeutic effect through irreversible acetylation of the cyclooxygenase (COX) enzymes, which catalyze the first step in the conversion of arachidonic acid to prostaglandins and thromboxanes. Two isoforms exist with distinct biological roles.

COX-1 (constitutive):

  • Expressed in most tissues, including platelets, and produces thromboxane A2 (TXA2, a potent promoter of platelet aggregation and vasoconstriction)
  • Because platelets lack a nucleus and cannot synthesize new protein, aspirin’s irreversible acetylation eliminates TXA2 production for the entire 7–10 day lifespan of the platelet
  • This mechanism underlies aspirin’s antiplatelet and cardioprotective effects and is fully achieved at doses as low as 75–100 mg daily

COX-2 (inducible):

  • Upregulated during inflammation and is the primary source of prostaglandin E2 (PGE2, a lipid mediator of pain, fever, and inflammatory signaling)
  • Higher doses (300–1,000 mg) are required for meaningful COX-2 inhibition, which is why low-dose aspirin produces minimal anti-inflammatory or analgesic effect
  • COX-2 in vascular endothelium produces prostacyclin (PGI2, an antiplatelet and vasodilatory prostaglandin), which is relatively spared at low doses, preserving the favorable platelet–endothelium balance

Cancer-relevant mechanisms:

  • Reduced COX-2-derived PGE2 in the tumor microenvironment may suppress immune evasion, angiogenesis, and tumor cell proliferation
  • Inhibition of platelet-mediated protection of circulating tumor cells (platelets cloak tumor cells in the bloodstream, shielding them from natural killer cells)
  • Modulation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a transcription factor regulating inflammation and cell survival) and Wnt/β-catenin signaling pathways implicated in colorectal carcinogenesis
  • Generation of aspirin-triggered specialized pro-resolving mediators (SPMs), including aspirin-triggered lipoxins and resolvins, that actively resolve inflammation rather than merely suppress it

Pharmacological properties:

  • Half-life: Acetylsalicylic acid itself has a plasma half-life of approximately 15–20 minutes, as it is rapidly hydrolyzed to salicylic acid (half-life 2–3 hours at low dose). The platelet effect is irreversible and lasts the platelet lifespan (7–10 days), making the pharmacokinetic half-life clinically less relevant
  • Selectivity: At low doses (75–100 mg), aspirin is approximately 170-fold more selective for platelet COX-1 than for endothelial COX-2
  • Tissue distribution: Acetylsalicylic acid is rapidly absorbed and distributed throughout extracellular fluid; protein binding is moderate (~50%) and increases at higher salicylate concentrations
  • Metabolism: Hydrolysis by esterases in plasma, liver, and erythrocytes to salicylic acid; conjugation in the liver via UGT1A6 (a UDP-glucuronosyltransferase enzyme that conjugates salicylates) and glycine conjugation (via the enzyme GLYAT). At gram-level doses, metabolism saturates and elimination becomes zero-order
  • Competing mechanistic explanations: Some authors argue that aspirin’s longevity-relevant effects may reflect AMPK (AMP-activated protein kinase, a cellular energy sensor) activation and mTOR (mechanistic target of rapamycin, a regulator of cell growth) inhibition at higher concentrations, while others argue these effects are achievable only at doses well above the 75–100 mg range and are therefore mechanistically distinct from the antiplatelet action

Historical Context & Evolution

Aspirin’s documented use as a cardiovascular agent began in 1948, when Lawrence Craven, a California general practitioner, observed that patients chewing aspirin gum after tonsillectomy bled more than expected. He hypothesized that aspirin’s antithrombotic properties might prevent heart attacks and began recommending it to his middle-aged male patients, publishing observational reports through the 1950s that were largely ignored by the medical establishment of the time.

The mechanistic basis arrived in the 1970s when John Vane demonstrated that aspirin inhibits prostaglandin synthesis, work for which he received the Nobel Prize in Physiology or Medicine in 1982. The first large-scale primary prevention trial, the Physicians’ Health Study (1989), randomized over 22,000 healthy male physicians to aspirin 325 mg every other day and reported a 44% reduction in first myocardial infarction (heart attack), a finding that drove widespread adoption.

Through the 1990s and 2000s, daily aspirin for primary prevention became routine practice for adults at moderate cardiovascular risk. Professional guidelines from the American Heart Association and the USPSTF endorsed its use across broad populations, and by 2017 an estimated 29 million Americans without established cardiovascular disease were taking it.

The paradigm shift came in 2018 with the near-simultaneous publication of three large randomized controlled trials. ASPREE (19,114 healthy older adults in Australia and the United States) found no benefit for disability-free survival, no cardiovascular benefit, and an unexpected increase in all-cause mortality driven by cancer deaths. ASCEND (15,480 adults with diabetes) found a modest 12% reduction in serious vascular events offset by a 29% increase in major bleeding. ARRIVE (12,546 adults at moderate cardiovascular risk) found no significant cardiovascular benefit, in part because the actual event rate in the control group was far lower than predicted — reflecting the success of modern statin and antihypertensive therapy in lowering baseline cardiovascular risk.

These results triggered cascading guideline revisions. The 2019 American College of Cardiology / American Heart Association guideline (ACC/AHA — professional cardiology societies whose membership and journal revenue are tied to cardiovascular guideline authority and to relationships with manufacturers of competing antithrombotic agents, a relevant conflict of interest) stated aspirin “should not be used routinely” in primary prevention; the 2022 USPSTF (a federally appointed panel whose recommendations drive insurer coverage in primary care, a structural interest in narrowing low-cost generic interventions toward higher-margin newer therapies) downgraded its primary prevention recommendation to a “C” for adults aged 40–59 with elevated cardiovascular risk and to a “D” recommendation (against use) for adults 60 and older. The actual findings of the early Craven and Physicians’ Health Study work — that aspirin meaningfully reduces first myocardial infarction in middle-aged men — have not been refuted; rather, the modern context (lower baseline cardiovascular risk, widespread statin use, and improved blood pressure control) has reduced the absolute benefit available to be captured. Critics of the wholesale shift point out that several of the pivotal modern trials enrolled lower-risk populations than the original positive trials and that the patent landscape favors newer agents, considerations that belong alongside the trial evidence rather than replacing it.

Expected Benefits

High 🟩 🟩 🟩

Cardiovascular Event Reduction in Secondary Prevention

For adults with established atherosclerotic cardiovascular disease (ASCVD, including prior myocardial infarction, ischemic stroke, peripheral artery disease, or coronary stenting), low-dose aspirin is a cornerstone of therapy with robust evidence from dozens of randomized controlled trials and meta-analyses. The Antithrombotic Trialists’ Collaboration meta-analysis demonstrated significant reductions in recurrent cardiovascular events and cardiovascular mortality. While this is not the primary focus of this review (which centers on use in adults without established disease), it provides the essential context that aspirin’s net clinical benefit is clearest and largest in secondary prevention.

Magnitude: Relative risk reduction (RR, the proportional difference in event rate between intervention and comparator groups) of approximately 20–25% for recurrent major cardiovascular events; number needed to treat (NNT, the number of people who must receive an intervention for one to benefit) of approximately 50–100 per year in secondary prevention populations.

Medium 🟩 🟩

Primary Prevention of Ischemic Cardiovascular Events ⚠️ Conflicted

The Zheng & Roddick (2019) JAMA meta-analysis of 13 primary prevention trials (164,225 participants) found aspirin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke with an HR of 0.89 (95% confidence interval — CI, the range likely to contain the true effect — 0.84–0.95). The absolute risk reduction was small (approximately 0.38% over 5 years) and was largely offset by increased major bleeding. The Laferrière et al. (2023) meta-analysis of 14 trials confirmed this pattern: aspirin reduces ischemic events without a demonstrated reduction in all-cause or cardiovascular mortality. The 2022 USPSTF evidence report concluded that for adults aged 40–59 with a 10-year ASCVD risk of 10% or greater, the net benefit is “small” and the decision should be individualized.

Magnitude: HR 0.89 (95% CI 0.84–0.95) for composite cardiovascular events; absolute risk reduction approximately 0.38% over 5 years; no statistically significant reduction in cardiovascular mortality (HR 0.94, 95% CI 0.86–1.03).

Colorectal Cancer Risk Reduction ⚠️ Conflicted

Long-term observational and trial follow-up data suggest that regular aspirin use for 6–10 years or more is associated with a 20–40% reduction in colorectal cancer incidence and a smaller reduction in colorectal cancer mortality, with the proposed mechanism centering on COX-2 inhibition in the colonic epithelium and modulation of platelet–tumor-cell interactions. The Petrelli et al. (2025) meta-analysis supports a modest protective effect, particularly for colorectal and liver cancers. However, the ASPREE trial found an unexpected increase in cancer-related mortality in older adults, and the 2022 USPSTF evidence review concluded that the evidence for an aspirin colorectal-cancer benefit was insufficient on its own to justify the recommendation. The signal is most consistent in younger adults with extended follow-up and least consistent in trials initiated in older populations.

Magnitude: Observational and pooled long-term trial follow-up suggest 20–40% relative risk reduction in colorectal cancer incidence after 6–10 years of use; shorter-follow-up trials generally do not show a significant cancer benefit.

Low 🟩

Reduction in Venous Thromboembolism

Some meta-analyses suggest low-dose aspirin reduces the risk of venous thromboembolism (VTE, a condition in which blood clots form in the deep veins and may travel to the lungs as pulmonary embolism) by approximately 25–40% relative to placebo, although this effect is less well established than aspirin’s arterial antithrombotic action. Evidence comes mainly from the WARFASA and ASPIRE trials in patients with prior unprovoked VTE, where aspirin reduced recurrence after anticoagulant withdrawal. The ASPREE trial reported a non-significant trend toward reduced VTE in the aspirin group.

Magnitude: Relative risk reduction of approximately 25–40% for recurrent VTE; absolute risk reduction is small in healthy populations because of the low baseline incidence.

Pre-eclampsia Prevention in High-Risk Pregnancy

Low-dose aspirin (typically 81–150 mg daily, started before 16 weeks gestation) reduces the incidence of pre-eclampsia (a pregnancy complication characterized by high blood pressure and organ dysfunction) in women at elevated risk. The ASPRE trial and subsequent meta-analyses report relative risk reductions in the range of 60–80% for preterm pre-eclampsia. This is an obstetric application outside the longevity scope of this review but is included for completeness because it is one of the few aspirin indications with unambiguously favorable risk-benefit data.

Magnitude: Relative risk reduction approximately 60–80% for preterm pre-eclampsia in high-risk pregnancies; absolute risk reduction varies by baseline risk.

Speculative 🟨

Specialized Pro-Resolving Mediator (SPM) Generation

Emerging preclinical research suggests aspirin may have effects beyond classical COX inhibition through its acetylation of COX-2, which redirects arachidonic and omega-3 metabolism toward aspirin-triggered lipoxins (ATLs) and aspirin-triggered resolvins. These specialized pro-resolving mediators actively terminate inflammatory programs rather than simply suppressing them and have been proposed as a partial mechanism for aspirin’s putative cancer-preventive and possibly longevity-supportive effects. Evidence in humans is limited to mechanistic biomarker studies, and translation to clinical longevity outcomes remains hypothetical.

Geroprotective and Senolytic-Adjacent Effects

A subset of preclinical work suggests aspirin or its metabolite salicylate can engage AMPK (AMP-activated protein kinase, a cellular energy sensor) and modestly inhibit mTOR signaling at high tissue concentrations, mechanisms shared with putative geroprotectors such as metformin and rapamycin. Some in vitro reports describe weak senolytic-adjacent effects (selective effects on damaged or senescent cells). These findings have not been demonstrated in human longevity trials and remain mechanistic speculation rather than established benefits at low antiplatelet doses.

Benefit-Modifying Factors

  • Baseline cardiovascular risk: Aspirin’s absolute benefit scales with baseline cardiovascular risk. The 10-year ASCVD risk score (calculated using the Pooled Cohort Equations) is the principal tool for estimating expected benefit. Adults with a 10-year risk below 10% derive minimal absolute benefit, while those at 15–20% or higher may have a more favorable benefit-to-bleeding ratio — a population that overlaps substantially with those who should already be on statin therapy.

  • Genetic polymorphisms: Variants in PTGS1 (the gene encoding COX-1), platelet glycoprotein receptors (GP IIb/IIIa, GPIa/IIa), and UGT1A6 (a UDP-glucuronosyltransferase enzyme that conjugates salicylates and influences clearance) may modulate aspirin response. Pharmacogenetic variation in cancer-related pathways such as PIK3CA (a gene frequently mutated in colorectal tumors) has been associated with differential colorectal-cancer chemoprevention benefit, although routine genotyping is not yet clinically standard.

  • Baseline biomarker levels: Adults with elevated high-sensitivity C-reactive protein (hs-CRP, a marker of low-grade systemic inflammation), elevated lipoprotein(a) (Lp(a), a genetically determined atherogenic particle), or elevated apolipoprotein B (apoB, the structural protein of atherogenic lipoproteins) tend to have higher background atherothrombotic risk and may derive larger absolute aspirin benefit. Conversely, optimized lipid biomarkers reduce expected aspirin benefit by lowering baseline event rates.

  • Sex-based differences: Older meta-analyses suggested aspirin preferentially reduces myocardial infarction in men and ischemic stroke in women; the more recent 2018 trials and subsequent meta-analyses have not confirmed strong sex-specific patterns. Current guidelines do not make sex-specific primary prevention recommendations. The pre-eclampsia indication is, by definition, female-only.

  • Pre-existing health conditions: Adults with type 2 diabetes mellitus have higher baseline ASCVD risk; ASCEND demonstrated a modest cardiovascular benefit offset by bleeding. Adults with familial hypercholesterolemia or elevated Lp(a) carry persistent residual atherothrombotic risk that may translate into greater absolute benefit. Adults with chronic kidney disease have altered platelet function and an unfavorable bleeding-to-benefit balance.

  • Age-related considerations: Younger adults (40–59) with elevated cardiovascular risk have a more favorable risk-benefit ratio because absolute bleeding risk is lower at younger ages while absolute cardiovascular risk is comparable. The ASPREE trial demonstrated that initiating aspirin in adults 70 and older confers no net benefit and likely causes harm; the 2022 USPSTF therefore recommends against initiation in adults 60 and older. For adults at the older end of the longevity-oriented audience (50–65), the calculus shifts year by year and warrants regular re-evaluation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Major Gastrointestinal Bleeding

The most significant and best-documented risk of daily aspirin use. The Zheng & Roddick (2019) meta-analysis found aspirin increased major bleeding with HR 1.43 (95% CI 1.30–1.56), driven primarily by gastrointestinal hemorrhage (HR 1.56). Even at low doses, aspirin inhibits COX-1-mediated prostaglandin production in the gastric mucosa, which reduces the protective mucous and bicarbonate layer and increases susceptibility to acid-induced erosion. Enteric coating does not reliably reduce gastric injury because the damage is mediated systemically (via platelet and prostaglandin inhibition) rather than by direct topical contact.

Magnitude: HR 1.43 for major bleeding; HR 1.56 for gastrointestinal bleeding; absolute risk increase approximately 0.47% over 5 years in primary prevention populations; number needed to harm (NNH, the number of people exposed for one to be harmed) approximately 200–250 per year.

Intracranial Hemorrhage

Aspirin increases the risk of hemorrhagic stroke (intracranial bleeding) by approximately 30–40%, partially offsetting the reduction in ischemic stroke. The Zheng & Roddick meta-analysis reported HR 1.33 (95% CI 1.13–1.58) for hemorrhagic stroke. While the absolute risk is low in healthy populations, intracranial hemorrhage carries high case fatality and substantial long-term morbidity, making it a particularly consequential adverse effect for the longevity-oriented audience whose decision frame extends over decades.

Magnitude: HR 1.33 for hemorrhagic stroke; absolute risk increase approximately 0.1% over 5 years; case fatality of hemorrhagic stroke is approximately 40–50%.

Medium 🟥 🟥

Dyspepsia and Gastric Erosion

Upper gastrointestinal symptoms — including heartburn, nausea, and epigastric pain (pain in the upper central abdomen) — affect approximately 10–20% of regular aspirin users. Endoscopic studies have demonstrated gastric erosions in up to 50% of daily aspirin users, most asymptomatic. Subclinical erosions may progress to clinically significant ulceration, particularly in the presence of additional risk factors such as Helicobacter pylori (H. pylori, a bacterium that colonizes the stomach lining and increases ulcer risk) infection or concurrent NSAID (nonsteroidal anti-inflammatory drug) use. Iron-deficiency anemia from chronic occult blood loss can develop over years of use and is sometimes the first clinical sign.

Magnitude: Dyspepsia in 10–20% of users; endoscopic gastric erosions in up to 50%; most erosions are subclinical.

Low 🟥

Easy Bruising and Prolonged Bleeding Time

Aspirin’s antiplatelet effect prolongs bleeding from minor cuts and injuries and increases susceptibility to bruising. While generally not medically dangerous, the effect is persistent for the 7–10 day platelet lifespan and is the reason aspirin must be discontinued at least 7 days before elective surgery or invasive procedures. For very high-impact activities (contact sports, technical mountaineering), the increased bruising and bleeding risk is a relevant practical consideration.

Magnitude: Bleeding time prolongation of approximately 2–3 times baseline; not quantified as an adverse event rate in major trials because it is considered an expected pharmacological effect.

Aspirin-Exacerbated Respiratory Disease and Hypersensitivity

Aspirin-exacerbated respiratory disease (AERD, also called Samter’s triad — a clinical syndrome combining aspirin sensitivity, nasal polyps, and asthma) affects approximately 0.5–2.5% of the general population and up to 10–20% of adults with asthma. Aspirin can trigger bronchoconstriction (narrowing of the airways), nasal congestion, and rarely anaphylaxis in sensitized individuals. Urticaria (hives) and angioedema (deep tissue swelling, including the face, lips, and airway) are also possible but uncommon.

Magnitude: AERD prevalence approximately 0.5–2.5% of the general population, up to 10–20% of adults with asthma; reactions range from mild nasal congestion to severe bronchospasm.

Tinnitus and Reversible Ototoxicity

Salicylate-induced tinnitus (perception of ringing or buzzing in the ears in the absence of an external sound) and mild reversible hearing loss are classical salicylate toxicity findings, more common at higher doses but occasionally reported at the upper end of the low-dose range, particularly in adults with reduced renal clearance. Effects typically resolve within days of discontinuation.

Magnitude: Not quantified in available studies for low-dose use; commonly reported only at gram-level salicylate doses.

Speculative 🟨

Increased Cancer Mortality in Older Adults

The ASPREE trial reported an unexpected increase in cancer-related mortality in adults aged 70 and older randomized to aspirin (HR 1.31, 95% CI 1.10–1.56). The signal has not been mechanistically explained. Hypothesized contributors include interference with immune surveillance of early cancers, acceleration of progression of subclinical cancers already present at baseline, or chance findings in extensive subgroup analyses. Extended ASPREE follow-up published through 2025 continues to inform this question. The signal has not been replicated in primary prevention trials initiated at younger ages, and its generalizability remains uncertain.

Acceleration of Macular Degeneration

A small number of observational analyses have reported an association between long-term aspirin use and an increased risk of advanced age-related macular degeneration (AMD, a leading cause of vision loss in older adults). The signal has not been confirmed in randomized trial data, and the proposed mechanism (subclinical retinal microhemorrhage) is plausible but unproven. The finding remains a hypothesis-generating observation rather than an established risk.

Risk-Modifying Factors

  • Age: Bleeding risk increases substantially with age. Adults over 70 have markedly higher incidences of gastrointestinal and intracranial bleeding than younger adults at equivalent doses, the principal driver of the USPSTF recommendation against initiation in adults 60 and older.

  • Genetic polymorphisms: Variants in PTGS1 (the gene encoding COX-1), platelet glycoprotein receptors (GP IIb/IIIa), and CYP2C9 (a hepatic cytochrome P450 enzyme involved in metabolism of salicylates and many co-prescribed drugs) may influence both efficacy and bleeding susceptibility. Routine pharmacogenetic testing for aspirin is not currently recommended.

  • Baseline biomarker levels: Adults with anemia (hemoglobin below the lower reference limit), thrombocytopenia (platelet count below approximately 100 × 10⁹/L), elevated INR (international normalized ratio, a measure of clotting time), or markedly elevated liver enzymes have a higher bleeding risk profile and should be evaluated and corrected before initiation where feasible.

  • Sex-based differences: Women may have a slightly higher rate of gastrointestinal bleeding from aspirin than men at equivalent doses; the data are not conclusive. Aspirin’s interaction with menstrual bleeding is generally not clinically meaningful at low doses but can be a consideration for women with heavy menstrual periods.

  • Pre-existing health conditions: Active or prior peptic ulcer disease, prior gastrointestinal bleeding, uncontrolled hypertension, advanced chronic kidney disease, advanced liver disease, bleeding disorders, prior intracranial hemorrhage, and recent ischemic stroke (within the first 24–48 hours) all substantially modify aspirin’s risk profile. H. pylori (a stomach bacterium that increases ulcer risk) infection approximately doubles the risk of aspirin-associated gastrointestinal bleeding; testing and treating before long-term initiation is recommended in multiple guidelines but inconsistently practiced.

  • Concurrent drugs and dietary patterns: Concurrent anticoagulant therapy, dual antiplatelet therapy, NSAID use, corticosteroid use, and SSRI (selective serotonin reuptake inhibitor, a common antidepressant class) use all amplify bleeding risk. High alcohol intake (>2 drinks daily) compounds gastrointestinal injury and bleeding risk.

  • Age-related considerations: For adults at the older end of the longevity-oriented audience (60–75), risk-benefit shifts year by year as baseline bleeding risk rises faster than baseline cardiovascular benefit; annual reassessment is appropriate, with particular attention to falls risk, cognitive change, and new medications.

Key Interactions & Contraindications

  • Anticoagulants (prescription drugs): Concurrent use with warfarin, heparin, or direct oral anticoagulants (DOACs, blood-thinning medications taken by mouth that block specific clotting factors; includes apixaban, rivaroxaban, edoxaban, and dabigatran) substantially increases bleeding risk. Severity: caution to absolute contraindication depending on indication. Mitigating action: combination only under direct physician supervision with clear indication (e.g., mechanical heart valve plus recent stent), with regular monitoring; consider gastroprotection.

  • Antiplatelet agents (prescription drugs): Concurrent use with P2Y12 inhibitors (a class of antiplatelet drugs that block the P2Y12 receptor on platelets to prevent platelet activation; includes clopidogrel, prasugrel, ticagrelor) creates dual antiplatelet therapy (DAPT), indicated after coronary stenting but substantially increasing bleeding risk. Severity: caution. Mitigating action: minimize duration to the clinically necessary period; reassess at each cardiology visit.

  • Nonsteroidal anti-inflammatory drugs (over-the-counter and prescription): Ibuprofen competes with aspirin for the COX-1 binding site and, if taken before aspirin, can block aspirin’s irreversible antiplatelet effect. Other NSAIDs (naproxen, diclofenac, celecoxib) compound gastrointestinal injury and bleeding. Severity: caution. Mitigating action: if ibuprofen is needed, take aspirin at least 30 minutes before ibuprofen, or 8 hours after; prefer acetaminophen (paracetamol) for routine analgesia.

  • Selective serotonin reuptake inhibitors (prescription drugs): SSRIs (sertraline, fluoxetine, escitalopram) impair platelet serotonin uptake required for normal aggregation. Severity: caution; risk of gastrointestinal bleeding increases approximately 2–3 fold. Mitigating action: consider gastroprotection with a PPI (proton pump inhibitor, a class of acid-suppressing medications including omeprazole and pantoprazole).

  • Methotrexate (prescription drug): Aspirin reduces renal clearance of methotrexate, increasing methotrexate toxicity, particularly at oncology doses. Severity: caution to absolute contraindication at high methotrexate doses. Mitigating action: monitor methotrexate levels; avoid combination at oncology dosing.

  • Corticosteroids (prescription drugs): Compound gastrointestinal injury and bleeding risk. Severity: caution. Mitigating action: add a PPI; reassess risk-benefit.

  • Antacids and PPIs (over-the-counter and prescription): Acetaminophen does not interact significantly. PPIs (omeprazole, pantoprazole, esomeprazole) reduce aspirin-related gastrointestinal bleeding by approximately 70–80%; this is a deliberately exploited additive effect rather than an adverse interaction.

  • Supplements with antiplatelet or anti-inflammatory effects: Fish oil (omega-3 fatty acids) has additive antiplatelet effects and modestly increases bleeding risk; clinical trials suggest the combination is generally safe at typical supplement doses. Vitamin E at high doses (≥400 IU/day) has mild antiplatelet activity. Ginkgo biloba, garlic extract (Allium sativum), and ginger (Zingiber officinale) have theoretical antiplatelet effects with limited clinical bleeding evidence in combination with aspirin. Curcumin (from Curcuma longa, turmeric) and resveratrol have mild antiplatelet activity. Nattokinase and lumbrokinase are fibrinolytic enzymes with additive antithrombotic effects. Severity: caution. Mitigating action: disclose all supplements to clinicians, particularly before procedures.

  • Other interventions: Concurrent regular alcohol intake compounds gastrointestinal bleeding risk; hyperbaric oxygen therapy and ablative dermatologic procedures warrant aspirin discussion in advance.

  • Populations who should avoid aspirin (or should not initiate it for primary prevention): Adults 60 years and older without established ASCVD (per the 2022 USPSTF “D” recommendation); adults with active peptic ulcer disease or prior gastrointestinal bleeding; adults with aspirin allergy or AERD (Samter’s triad); adults with bleeding disorders or thrombocytopenia (platelet count <100 × 10⁹/L); adults on full-dose anticoagulant therapy without a specific indication for combination; adults with uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic ≥100 mmHg); adults with severe hepatic impairment (Child-Pugh Class C, the most severe category of cirrhosis); adults with advanced chronic kidney disease (eGFR — estimated glomerular filtration rate, a measure of kidney function — <30 mL/min/1.73m²); pregnant women in the third trimester (risk of premature closure of the ductus arteriosus, a fetal blood vessel); and children and adolescents during viral illness (risk of Reye’s syndrome, a rare but serious condition causing acute liver and brain swelling).

Risk Mitigation Strategies

  • Test and treat H. pylori before initiation: Stool antigen or urea breath testing for H. pylori prior to long-term aspirin use, with eradication treatment if positive, substantially reduces gastrointestinal bleeding risk. This is recommended by multiple guidelines but inconsistently practiced.

  • Use a PPI in elevated-bleeding-risk individuals: Add a proton pump inhibitor (omeprazole 20–40 mg daily, pantoprazole 20–40 mg daily, or equivalent) for adults over 60, with prior peptic ulcer or gastrointestinal bleeding, on concurrent NSAID, SSRI, or corticosteroid therapy, or with H. pylori-positive history. PPIs reduce aspirin-related upper gastrointestinal bleeding by approximately 70–80%.

  • Maintain blood pressure control before and during use: Confirm blood pressure is below 140/90 mmHg and ideally below 130/80 mmHg before initiating aspirin and at every follow-up; uncontrolled hypertension amplifies hemorrhagic stroke risk and is the most modifiable contributor to intracranial bleeding.

  • Avoid concurrent NSAIDs unless medically necessary: Use acetaminophen (paracetamol) for routine analgesia; reserve NSAIDs for short-course use under specific indication. If ibuprofen is unavoidable, take aspirin at least 30 minutes before ibuprofen to preserve antiplatelet acetylation.

  • Plan procedural discontinuation: Discontinue aspirin at least 7 days before elective surgery or major dental procedures to allow platelet function to recover. Resume at the surgeon’s discretion once hemostasis is confirmed. For low-bleeding-risk procedures (most dental work, simple skin biopsies, cataract surgery), continuation is often acceptable.

  • Use plain (immediate-release) aspirin and limit dose to 81–100 mg: Avoid enteric-coated formulations where possible (variable bioavailability without bleeding-risk reduction) and avoid doses above 100 mg unless specifically indicated, since higher doses increase bleeding without clear additional cardiovascular benefit (per ADAPTABLE).

  • Limit alcohol intake to ≤1 drink daily and avoid binge drinking: Alcohol compounds gastric injury and increases bleeding risk; this is a frequently underappreciated modifiable factor.

  • Recognize and act on bleeding warning signs: Educate on recognition of melena (black tarry stools indicating digested blood), hematemesis (vomiting blood, including “coffee-grounds” emesis), unexplained fatigue or pallor (potential anemia from occult blood loss), and severe headache or focal neurologic symptoms (possible intracranial bleeding). Do not attribute these to benign causes without medical evaluation.

  • Re-evaluate risk-benefit annually: Recalculate 10-year ASCVD risk, review concurrent medications, screen for falls and cognitive change, repeat targeted laboratory testing, and explicitly reconsider whether aspirin remains net-beneficial — particularly across the 60–75 age range, where risk-benefit shifts most rapidly.

Therapeutic Protocol

The standard protocol for low-dose aspirin in primary prevention follows the 2022 USPSTF recommendations and 2019 ACC/AHA primary prevention guideline, with practical refinements from clinicians who use it within a longevity-oriented framework.

  • Standard dose: 81 mg orally once daily (the standard “baby aspirin” formulation in the United States). In Europe and Australia, 75 mg or 100 mg formulations are common and clinically equivalent. Peter Attia has described taking 81 mg daily for primary prevention while explicitly acknowledging the modest evidence, framing the decision as individualized risk-benefit. Competing therapeutic approaches exist: integrative practitioners such as Chris Kresser argue that for most healthy adults the bleeding risk outweighs cardiovascular benefit and propose alternatives (omega-3 fatty acids, curcumin, nattokinase) as antiplatelet and anti-inflammatory substitutes, and these should be evaluated on their own evidence.

  • Formulation: Plain (immediate-release) aspirin is generally preferred over enteric-coated formulations. Enteric coating was designed to reduce gastric irritation but evidence suggests it does not meaningfully reduce gastrointestinal bleeding (which is mediated systemically through platelet inhibition, not direct topical contact) and may reduce bioavailability by 40–50% in some individuals — a possible contributor to the “aspirin resistance” phenomenon.

  • Best time of day: Traditionally taken in the morning. A 2013 randomized crossover study (ASPIRE) reported that bedtime dosing produced better 24-hour platelet inhibition. Current guidelines do not specify a preferred time. Consistency of timing matters more than the specific time chosen; taking with food reduces gastric irritation.

  • Half-life and pharmacokinetics: Acetylsalicylic acid has a plasma half-life of approximately 15–20 minutes (rapidly hydrolyzed to salicylic acid, half-life 2–3 hours at low dose). The clinically relevant half-life is the platelet lifespan (7–10 days), since aspirin’s effect is irreversible.

  • Single vs. split dose: The full daily dose is taken as a single tablet. There is no rationale for splitting, since complete platelet COX-1 acetylation occurs within the first hour and persists for the platelet lifespan.

  • Genetic considerations: PTGS1 polymorphisms, platelet receptor variants, and UGT1A6 variants may influence aspirin response. Routine pharmacogenomic testing is not recommended, and no genotype-guided dosing protocols are clinically established.

  • Sex-based differences: No sex-specific dose adjustments are recommended for cardiovascular primary prevention. Women considering aspirin during high-risk pregnancy use a separate obstetric protocol (typically 81–150 mg started before 16 weeks gestation under obstetric supervision) outside the scope of this longevity review.

  • Age-related considerations: The 2022 USPSTF recommends against initiating aspirin in adults 60 and older. For adults aged 40–59 with a 10-year ASCVD risk of 10% or greater, the decision is individualized. For adults already on long-term aspirin who turn 60, the decision to continue is more nuanced — the evidence against initiation is stronger than the evidence supporting discontinuation in established users — and should be revisited annually.

  • Baseline biomarker assessment: Before starting, calculate 10-year ASCVD risk (Pooled Cohort Equations), measure fasting lipids (preferably with apoB), hs-CRP, hemoglobin and ferritin, basic metabolic panel including eGFR, and blood pressure on at least two occasions; consider Lp(a) once in a lifetime. H. pylori testing (stool antigen or urea breath test) is recommended before long-term initiation.

  • Pre-existing health conditions: Adults with established ASCVD have a separate, stronger indication for secondary prevention (outside the scope of this primary-prevention-focused review). Adults with diabetes should incorporate ASCEND-style risk-benefit thinking. Adults with chronic kidney disease have altered platelet function and elevated bleeding risk; aspirin requires individualized clinician input. Adults with chronic liver disease, prior peptic ulcer, or prior intracranial hemorrhage require particular caution.

Discontinuation & Cycling

  • Long-term vs. short-term use: Low-dose aspirin for primary prevention is intended as a long-term intervention, since cardiovascular and any colorectal-cancer-preventive effects accrue over years of daily use. The decision to continue should be revisited annually, especially across the 60–75 age range.

  • Withdrawal effects: No pharmacological withdrawal syndrome occurs with aspirin discontinuation. Observational and mechanistic data have raised concern about a transient “rebound” increase in cardiovascular events in the weeks after cessation, particularly in adults with established cardiovascular disease, attributed to a brief rise in platelet reactivity as new uninhibited platelets enter the circulation. The rebound signal is most relevant in secondary prevention and around abrupt perioperative discontinuation.

  • Tapering protocol: No formal tapering protocol exists for primary prevention; aspirin can simply be discontinued. When stopping aspirin in someone who has been on it for years, ensuring blood pressure, lipid, and glucose control are well-managed and avoiding discontinuation during periods of increased thrombotic risk (immediately after surgery, during prolonged immobilization, during acute infection) is reasonable.

  • Cycling for maintenance of efficacy: Cycling is not recommended. Aspirin’s antiplatelet effect requires continuous daily use to maintain inhibition of newly produced platelets, and intermittent dosing protocols are not supported by clinical evidence.

  • Re-initiation after planned breaks: When restarting aspirin after a procedural break, the standard 81 mg daily dose can be resumed without re-titration. The full platelet effect is achieved within 24–48 hours.

Sourcing and Quality

Low-dose aspirin (81 mg) is available over the counter in most jurisdictions and is among the least expensive medications available.

  • Formulation selection: Distinguish among (1) plain (immediate-release) tablets, generally preferred; (2) chewable tablets, useful in acute coronary settings and acceptable for chronic dosing; (3) enteric-coated tablets, marketed as gastroprotective but with variable bioavailability and without convincing reduction in gastrointestinal bleeding; and (4) buffered formulations, which offer modest gastric tolerability benefit at minor cost premium.

  • What to look for: Pharmaceutical-grade tablets manufactured under FDA-regulated Good Manufacturing Practice (GMP) standards and packaged in moisture-resistant containers with clear lot numbers and expiration dates. Because aspirin is a well-established generic pharmaceutical, third-party testing of the type used for dietary supplements is generally not required.

  • Reputable brands: Bayer Low Dose Aspirin and St. Joseph Aspirin are the most established branded products in the United States. Generic 81 mg aspirin from major retailers (CVS, Walgreens, Costco/Kirkland, Rite Aid) is bioequivalent and substantially less expensive. In Europe, ASS-ratiopharm, Acard, and Cardirene are commonly used 75–100 mg generics.

  • Storage and stability: Aspirin should be stored in a cool, dry place in its original moisture-resistant container, with a typical shelf life of 2–3 years. Hydrolysis to salicylic acid and acetic acid produces a strong vinegar smell, indicating degradation; visibly degraded or strongly vinegar-smelling tablets should be discarded.

  • Compounded or specialized formulations: Compounded low-dose aspirin is generally not necessary because mass-produced 81 mg tablets are uniformly available. Specialty formulations (combination aspirin–PPI products such as aspirin–omeprazole) exist and can simplify gastroprotection in adults at elevated bleeding risk.

Practical Considerations

  • Time to effect: Antiplatelet effect begins within 30–60 minutes of ingestion, with near-complete platelet COX-1 inhibition within 1 hour. Cardiovascular event reduction accrues over months to years of consistent daily use. Colorectal cancer chemoprevention, if real at low dose, appears to require approximately 5–10 years of continuous use to manifest.

  • Common pitfalls: The most common error is initiating aspirin without a structured risk-benefit assessment, often based on outdated advice or family tradition. Other recurring mistakes include taking ibuprofen on the same day in a way that blocks aspirin’s antiplatelet acetylation, assuming enteric coating provides meaningful gastroprotection, continuing aspirin past the age at which risks outweigh benefits without reassessment, and abrupt perioperative discontinuation without a clear reinitiation plan.

  • Regulatory status: Aspirin is available over the counter in most jurisdictions. The FDA declined to approve Bayer’s application to market aspirin specifically for primary prevention of cardiovascular disease in 2014, citing insufficient evidence of net benefit. Aspirin remains FDA-approved for secondary prevention and for various analgesic and antipyretic indications.

  • Cost and accessibility: Extremely affordable and widely accessible. A 30-day supply of generic 81 mg aspirin typically costs $1–4 USD; branded products cost $5–15. Cost is not a barrier to access in any developed economy.

Interaction with Foundational Habits

  • Sleep: Direct, generally neutral. Aspirin does not significantly affect sleep architecture or quality. A 2013 randomized crossover study (ASPIRE) reported that bedtime dosing produced more uniform 24-hour platelet inhibition; clinical significance for outcomes is uncertain. Practical consideration: if bedtime dosing is preferred, take with a small snack to minimize gastric irritation.

  • Nutrition: Indirect, largely supportive. Chronic subclinical gastrointestinal blood loss can contribute to iron deficiency over years of use, particularly in premenopausal women and older adults; periodic ferritin monitoring is advisable. Taking aspirin with food reduces gastric irritation. Diets rich in omega-3 fatty acids (oily fish, walnuts, flaxseed) may modestly potentiate antiplatelet effect; high-alcohol diets compound bleeding risk. Practical consideration: take with food, monitor iron status, limit alcohol to ≤1 drink daily.

  • Exercise: Indirect, generally neutral. Aspirin does not impair exercise performance or training adaptation. Aspirin-associated subclinical gastrointestinal bleeding can increase during prolonged endurance exercise (when splanchnic blood flow drops), and bruising from impacts may be more pronounced in contact sports. Practical consideration: take after, rather than immediately before, prolonged endurance sessions; consider holding aspirin around very-high-impact events under clinician guidance.

  • Stress management: Indirect, generally neutral. Aspirin does not directly affect cortisol (the body’s primary stress hormone) or the hypothalamic–pituitary–adrenal axis (HPA, the hormonal system that regulates the stress response). Chronic psychological stress increases cardiovascular risk and platelet reactivity, which may theoretically enhance aspirin’s relative benefit. There is no evidence that aspirin interacts meaningfully with meditation, breathwork, or other stress-management practices. Practical consideration: aspirin is not a substitute for stress management; the two operate on different but additive risk pathways.

Monitoring Protocol & Defining Success

Baseline laboratory testing is performed before initiating low-dose aspirin to establish reference values, screen for contraindications (anemia, thrombocytopenia, occult bleeding, uncontrolled hypertension, advanced kidney or liver disease, H. pylori infection), and frame the cardiovascular risk picture.

Ongoing monitoring follows a cadence of repeat testing at 3 months after initiation, then at 12 months, and at least annually thereafter for adults at the older end of the longevity-oriented audience or with elevated bleeding-risk factors.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Complete blood count (CBC) with differential Hemoglobin within sex-specific reference; MCV 85–95 fL Detects occult gastrointestinal blood loss, iron deficiency, and thrombocytopenia CBC = complete blood count; MCV = mean corpuscular volume, the average size of red blood cells. Falling hemoglobin or rising MCV variation can be the first sign of subclinical bleeding
Ferritin 50–150 ng/mL (women); 50–300 ng/mL (men) (functional) Detects iron depletion from chronic subclinical gastrointestinal blood loss Conventional lower limit is 12–15 ng/mL; functional medicine targets are higher. Fasting sample preferred; check at baseline and annually
Fecal immunochemical test (FIT) Negative Screens for subclinical gastrointestinal bleeding FIT replaces older guaiac-based tests (which can give false positives with aspirin); recommended at baseline and during routine colorectal cancer screening
Blood pressure <130/80 mmHg (functional) Ensures uncontrolled hypertension does not amplify hemorrhagic stroke risk Conventional target is <140/90 mmHg. Measure seated after 5 minutes rest; uncontrolled blood pressure is a relative contraindication
Fasting lipid panel (TC, LDL-C, HDL-C, TG, apoB) LDL-C <100 mg/dL; apoB <80 mg/dL; TG <100 mg/dL; HDL-C >50 mg/dL (functional) Frames the overall cardiovascular risk context within which aspirin is evaluated TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; apoB = apolipoprotein B (atherogenic particle count). 12-hour fast preferred; apoB does not require fasting
Lipoprotein(a) <30 mg/dL or <75 nmol/L Identifies a genetically determined atherothrombotic risk factor; very high Lp(a) shifts aspirin toward favorable Lp(a) = lipoprotein(a). Genetically determined; one-time measurement is generally sufficient
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L (functional) Tracks low-grade systemic inflammation, a residual cardiovascular risk indicator hs-CRP = high-sensitivity C-reactive protein. Avoid testing during acute illness, which transiently elevates hs-CRP
HbA1c <5.5% (functional) Identifies metabolic risk that modifies aspirin’s risk-benefit balance HbA1c = glycated hemoglobin, a marker of average blood sugar over 2–3 months. Conventional “normal” is <5.7%; functional optimal is <5.5%. No fasting required
Estimated glomerular filtration rate (eGFR) >90 mL/min/1.73m² Identifies chronic kidney disease, which alters platelet function and bleeding risk eGFR = estimated glomerular filtration rate, calculated from serum creatinine. Conventional “normal” is >60; functional range is >90
Liver enzymes (ALT, AST) <25 U/L (functional) Identifies hepatic impairment, which modifies bleeding risk and salicylate clearance ALT = alanine aminotransferase; AST = aspartate aminotransferase. AST can also rise after intense exercise; time blood draw at least 48 hours after strenuous activity
H. pylori (stool antigen or urea breath test) Negative Identifies infection that approximately doubles aspirin-related gastrointestinal bleeding risk H. pylori = Helicobacter pylori. Recommended once before long-term aspirin initiation; eradication treatment if positive
10-year ASCVD risk score Recalculated annually Frames the aspirin initiation and continuation decision ASCVD = atherosclerotic cardiovascular disease. Calculated using the ACC/AHA Pooled Cohort Equations

Qualitative markers to track:

  • Absence of cardiovascular events (myocardial infarction, ischemic or hemorrhagic stroke, transient ischemic attack)
  • Absence of clinically apparent bleeding (no melena, hematemesis, hematuria, easy bruising beyond baseline, prolonged epistaxis, or unexpected gum bleeding)
  • Stable hemoglobin and ferritin trajectories over years
  • Stable blood pressure under target
  • Absence of new gastrointestinal symptoms (heartburn, epigastric pain, nausea)
  • Absence of new neurologic symptoms (severe headache, sudden visual change, focal weakness)
  • Annual reassessment confirming continued favorable risk-benefit profile

Emerging Research

Several active and recently completed clinical trials, plus emerging research themes, are likely to shape the understanding of low-dose aspirin over the coming years.

  • Extended ASPREE follow-up: Long-term observational follow-up of ASPREE participants (PMID 40796244) provides additional data on cardiovascular events, major bleeding, and the cancer mortality signal in older adults beyond the original 4.7-year median, helping determine whether the cancer mortality signal persists or attenuates.

  • ADAPTABLE 81 mg vs. 325 mg in established cardiovascular disease: The pragmatic ADAPTABLE trial (NCT02697916) compared aspirin 81 mg versus 325 mg daily in over 15,000 patients with established cardiovascular disease, with primary results favoring 81 mg as the preferred chronic dose. Ongoing analyses examine subgroups by sex, race, and obesity.

  • ATTACK trial of aspirin in chronic kidney disease: A Phase 3 trial (NCT03796156) of low-dose aspirin for cardiovascular primary prevention in adults with chronic kidney disease — a population systematically excluded from prior primary prevention trials. The trial was terminated early after enrolling 4,633 of a planned 25,210 participants because the planned recruitment total was not achievable within the funded timeframe; analyses of the available data are expected to inform aspirin’s risk-benefit balance in this population despite the underpowered sample.

  • Add-Aspirin colorectal cancer prevention trial: The Add-Aspirin platform trial (NCT02804815) is testing whether daily aspirin (100 mg or 300 mg) after curative-intent treatment of early-stage colorectal, breast, esophago-gastric, or prostate cancer reduces recurrence and mortality, with an estimated study completion date of October 2026. Primary results are expected to substantially clarify aspirin’s role in cancer chemoprevention.

  • ASPirin Eradicating Recurrent Events (ASPIRE) and successors in venous thromboembolism: Ongoing analyses of pooled VTE-secondary-prevention data are refining aspirin’s role versus DOACs after initial anticoagulant therapy.

  • Pharmacogenomic aspirin response in colorectal cancer chemoprevention: Research into PIK3CA-mutant colorectal cancer (Liao et al., 2012) and related genomic predictors of differential aspirin chemoprevention benefit is moving toward prospective testing, with implications for genotype-guided primary prevention decisions.

  • Bodyweight-adjusted aspirin dosing: Rothwell et al., 2018 reported in an individual-patient-data analysis of 10 trials that aspirin 75–100 mg was effective in preventing cardiovascular events only in adults weighing under 70 kg, with higher doses required for heavier individuals. Whether this finding can be confirmed in dedicated randomized trials and translated into bodyweight-adjusted dosing recommendations is an active question.

  • Aspirin and the gut microbiome: Preliminary studies suggest aspirin alters gut bacterial composition, and that the microbiome may influence aspirin bioavailability and efficacy. This line of research could eventually inform microbiome-guided prescribing.

  • Pre-eclampsia prevention generalization: Ongoing research is examining whether aspirin started in early pregnancy at 81–150 mg daily might benefit broader populations of pregnant women than current high-risk-only guidelines, with potential to expand the indication on the favorable-evidence side.

  • Aspirin during cancer treatment: Elwood et al., 2024 systematically reviewed evidence on aspirin during cancer treatment (versus prevention), finding mixed but generally encouraging results for colorectal, breast, and prostate cancers. Several Phase 3 trials are extending this work.

Conclusion

Low-dose aspirin occupies a uniquely complex position in preventive medicine. For adults with established heart disease, the evidence remains strong and aspirin continues to be a standard of care. For adults without established heart disease — the focus of this review — the picture has shifted fundamentally over the past decade.

In broad primary prevention populations, low-dose aspirin produces a statistically significant but clinically modest reduction in cardiovascular events, largely offset by a meaningful increase in major bleeding, and without a demonstrated reduction in cardiovascular or overall mortality. The potential colorectal cancer benefit is biologically plausible, supported by long-term observational and trial follow-up data, and most apparent after several years of continuous use; it is complicated by an unexplained signal of higher cancer mortality in older adults seen in one large trial.

Risk and benefit shift substantially with age, baseline cardiovascular risk, bleeding risk factors, and the modern background of widespread statin use and improved blood pressure control. Structural-bias considerations belong alongside the trial evidence: aspirin is an inexpensive generic, while major government and cardiology guideline bodies operate within an ecosystem that derives revenue and influence from the broader pharmaceutical landscape, including newer, patent-protected blood-thinning alternatives. For a longevity-oriented adult, low-dose aspirin is best understood as a targeted intervention chosen for an individualized rationale and re-evaluated regularly.

Top - Benefits - Risks - Protocol